NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272

BMC Pharmacology

Volumn 1, Issue , 2001, Pages

  Becker, Eva Maria ^a   Alonso Alija, Cristina ^a   Apeler, Heiner ^a   Gerzer, Rupert ^c   Minuth, Torsten ^a   Pleiß, Ulrich ^a   Schmidt, Peter ^a   Schramm, Matthias ^a   Schröder, Henning ^b   Schroeder, Werner ^a   Steinke, Wolfram ^a   Straub, Alexander ^a   Stasch, Johannes Peter ^a  

^a BAYER AG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c GERMAN AEROSPACE CENTER DLR   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; BAY 50 6038; BAY 50 8364; BAY 51 9491; CYSTEINE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HEME; NITRIC OXIDE; NITRIC OXIDE DONOR; PYRAZOLOPYRIMIDINE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PURIFICATION; ENZYME SUBUNIT; NONHUMAN; PHOTOAFFINITY LABELING; POLYACRYLAMIDE GEL ELECTROPHORESIS; RADIOACTIVITY; THIN LAYER CHROMATOGRAPHY; THROMBOCYTE AGGREGATION INHIBITION; ULTRAVIOLET RADIATION; VASODILATATION;

EID: 2642541002     PISSN: 14712210     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2210-1-13     Document Type: Article

References (46)

1. Wedel BJ, Garbers DL: New insights on the functions of the guanylyl cyclase receptors. FEBS Letters 1997, 410:29-33
2. Zabel U, Hausler C, Weeger M, Schmidt HH: Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione S-transferase affinity tag. J Biol Chem 1999, 274:18149-18152
3. Koglin M, Vehse K, Budaeus L, Scholz H, Behrends S: Nitric oxide activates the beta 2 subunit of soluble guanylyl cyclase in the absence of a second subunit. J Biol Chem 2001, 276:30737-30743
4. Lincoln TM: Cyclic GMP and mechanisms of vasodilation. Pharmac Ther 1989, 41:479-502
5. Moncada S, Higgs EA: Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995, 9:1319-1330
6. Zhuo M, Hawkins RD: Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system. Rev Neurosci 1995, 6:259-277
7. Arnold WP, Mittal CK, Katsuki S, Murad F: Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′ -cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977, 74:3203-3207
8. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM: YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84:4226-4233
9. Mülsch A, Bauersachs J, Schaefer A, Stasch JP, Kast R, Busse R: Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 1997, 120:681-689
10. Friebe A, Schultz G, Koesling D: Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 1996, 15:6863-6868
11. Hoenicka M, Becker EM, Apeler H, Sirichoke T, Schröder H, Gerzer R, Stasch JP: Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol Med 1999, 77:14-23
12. Brüne B, Schmidt KU, Ullrich V: Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eu. J Biochem 1990, 192:683-688
13. Friebe A, Koesling D: Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998, 53:123-127
14. Stone JR, Marletta MA: Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem Biol 1998, 5:255-261
15. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM: YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 1995, 116:1973-1978
16. Wu CC, Ko FN, Teng CM: Inhibition of platelet adhesion to collagen by cGMP-elevating agents. Biochem Biophys Res Commun 1997, 231:412-416
17. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC: YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997, 320:161-166
18. Becker EM, Schmidt P, Schramm M, Schröder H, Walter U, Hoenicka M, Gerzer R, Stasch JP: The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets. Cardiovasc Pharmacol 2000, 35:390-397
19. Ruetten H, Mülsch A, Schoenafinger K, Martorana PA: The NO-independent activator of the soluble guanylyl cyclase YC-1: pharmacological profile and tolerance studies. Naunyn-Schmiedebergs Arch Pharmacol 1998, 358:310
20. Becker EM, Wunder F, Kast R, Robyr C, Hoenicka M, Gerzer R, Schröder H, Stasch JP: Generation and characterization of a stable soluble guanylate cyclase-overexpressing CHO cell line. Nitric Oxide 1999, 3:55-66
21. Friebe A, Russwurm M, Mergia E, Koesling D: A point-mutated guanylyl cyclase with features of the YC-1-stimulated enzyme: implications for the YC-1 binding site? Biochem 1999, 38:15253-15257
22. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feuerer A, Gerzer R, Minuth T, Perzborn E, Pleiß U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M: NO-independent regulatory site on soluble guanylate cyclase. Nature 2001, 410:212-215
23. Yoshina S, Kuo SC: Studies on heterocyclic compounds. XXXVII. Synthesis of furo[3,2-c]pyrazole derivatives. (5). Synthesis of alpha-methyl-1-(p-substituted phenyl)-3-phenylfuro[3,2-c]pyrazole-5-acetic acids. Yakugaku Zasshi 1978, 98:204-208
24. Straub A, Feurer A, Alonso-Alija C, Stahl E, Stasch JP, Perzborn E, Hutter J, Dembowsky K: Patent Application No. WO-0006568. Patent Prio 1998. 07.29
25. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, Fürstner C: NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001, 11:781-784
26. Carnazzi E, Aumelas A, Barberis C, Guillon G, Seyer R: A new series of photoactivatable and iodinatable linear vasopressin antagonists. J Med Chem 1994, 37:1841-1849
27. Devos A, Remion J, Frisque-Hesbain A, Colens A, Ghosez L: Synthesis of acyl halides under very mild conditions. J Chem Soc Chem Commun 1979, 24:1180-1181
28. Li Q, Chu DT, Claiborne A, Cooper CS, Lee CM, Raye K, Berst KB, Donner P, Wang W, Hasvold L, et al: Synthesis and structure-activity relationships of 2- pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. J Med Chem 1996, 39:3070-3088
29. Gerzer R, Boehme E, Hofmann F, Schultz G: Soluble guanylate cyclase purified from bovine lung contains heme and copper. FEBS Lett 1981, 132:71-74
30. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685
31. Ahr HJ, Steinke W: Imaging Plate: Vasodilation and first experience with quantitative studies in whole-body autoradiography during drug development. Xenobiotic Metab Dispos 1994, 9:371-378
32. Schagger H, Aquila H, von Jagow G: Coomassie blue-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for direct visualization of polypeptides during electrophoresis. Anal Biochem 1988, 173:201-205
33. Towbin H, Staehlin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354
34. Thomas R, Pfeuffer T: Photoaffinity labeling of GTP-binding proteins. Meth Enzymol 1991, 195:280-286
35. Pandurangi RS, Karra SR, Kuntz RR, Volkert WA: Recent trends in the evaluation of photochemical insertion characteristics of heterobifunctional perfluoroaryl azide chelating agents: biochemical implications in nucleal medicine . Photochem Photobiol 1997, 65:208-221
36. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B: Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 1995, 48:184-188
37. Brunner F, Schmidt K, Nielsen EB, Mayer B: Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. J Pharmacol Exp Ther 1996, 277:48-53
38. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B: Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996, 50:1-5
39. Nakane M, Arai K, Saheki S, Kuno T, Buechler W, Murad F: Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung. J Biol Chem 1990, 265:16841-16845
40. Zabel U, Weeger M, La M, Schmidt HHHW: Human soluble guanylate cyclase: functional expression and revised isoenzyme family. Biochem J 1998, 335:51-57
41. Zhao Y, Marletta MA: Localization of the heme binding region in soluble guanylate cyclase. Biochem 1997, 36:15959-15964
42. Zhao Y, Schelvis JPM, Babcock GT, Marletta MA: Identification of histidine 105 in the beta1 subunit of soluble guanylate cyclase as the heme proximal ligand. Biochem 1998, 37:4502-4509
43. Kharitonov VG, Sharma VS, Magde D, Koesling D: Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Biochem 1999, 38:10699-10706
44. Hobbs AJ: Soluble guanylate cyclase: the forgotten sibling. 1997, 18:484-491
45. Koglin M, Behrends S, Scholz H: Cloning and expression of the rat D2 subunit of nitric oxide sensitive guanylyl cyclase and analysis of deletion mutants. Naunyn-Schmiedeberg s Arch Pharmacol 2001, 363 (Supplement):187
46. Martin E, Lee Y-C, Murad F: YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc Natl Acad Sci USA 2001, 23:12938